Can You Advertise Compounded GLP‑1s on Google Ads?

The direct answer

Yes, compounded GLP‑1 programmes are advertised on Google — but almost never by targeting the drug names. Certified telehealth and pharmacy advertisers may reference compounded semaglutide or tirzepatide in tightly constrained ways, while keyword-targeting those terms remains restricted to advertisers holding pharmaceutical certification. For everyone else the compliant route is to advertise the programme, not the molecule.

Most disapprovals in this category are not a mystery once you separate the two systems. Google reviews what your ad says, and separately reviews what you bid on. A clinic can write perfectly compliant ad copy and still be shut down because its keyword list is full of brand drug names.

What changed and what did not

In October 2025 Google adjusted its restricted drug terms policy to permit prescription drug terms in ad text and landing pages in limited non-promotional contexts — public health information, academic publication, legal notices and similar. Coverage of the change was widely misread as a general relaxation.

Surface	Status for a non-certified advertiser
Keyword targeting on drug names	Restricted. This is the wall.
Drug names in ad headlines / descriptions	Restricted for promotional use; narrow non-promotional exceptions
Drug names on landing pages	Context-dependent; promotional framing pulls in healthcare policy
Programme and service language	Generally available, subject to claims rules
Branded terms (your own clinic name)	Available and usually under-used

How to talk about a compounded product

Compounded semaglutide is not Ozempic, and treating the two as interchangeable in your marketing creates two separate problems: a healthcare-policy problem, because you are implying an approved product you do not dispense, and a misrepresentation problem, because the shopper is being told something that is not accurate.

What holds up better:

• Name it explicitly. “Compounded semaglutide” where the term is used at all, never the brand name as a stand-in.
• Describe the programme. Consultation, eligibility review, prescriber oversight, labs, follow-up cadence, what is and is not included.
• Say who is not eligible. Clear exclusion criteria read as clinical seriousness to both reviewers and prospects.
• Name the pharmacy relationship at the level you are able to. Vagueness about who compounds and dispenses is a transparency flag.
• Drop outcome numbers you cannot source. Average weight-loss percentages lifted from trial data for a different product are the single most common claim problem we see.

A campaign structure that survives review

The structure we generally reach for with GLP‑1 and medical weight-loss clinics separates risk by campaign so a disapproval in one place cannot take the whole account down.

1. Brand campaign. Exact and phrase on your clinic name and misspellings. Cheapest conversions in the account and a stability floor while other campaigns are in review.
2. Service intent campaign. Medical weight loss, weight loss clinic, physician-supervised weight loss, telehealth weight loss programme, plus your city terms if you have a physical footprint.
3. Eligibility and consultation intent. Queries about qualifying, cost, insurance and how programmes work. These convert into consultations well and stay clear of drug terms.
4. Competitor and category handled cautiously, with tight negatives and no drug names.
5. A shared negative list applied account-wide covering brand drug names, dosage queries, “buy” + drug name, grey-market phrasing and research-chemical language.

Performance Max is where clinics get into trouble fastest, because you control less of the query surface. If you run it, run it with campaign-level negatives and brand exclusions in place from day one — see Performance Max for peptide and telehealth accounts.

The landing page is where most GLP‑1 accounts fail

Ad copy gets attention because disapprovals name it. In practice the landing page decides more outcomes, because AdsBot crawls it, human reviewers read it, and it is where claims accumulate over months of well-meaning content marketing.

What a defensible GLP‑1 programme page contains:

• An accurate description of what is being sold: a medical programme with clinical oversight, not a product listing for a drug.
• Explicit compounded language wherever a formulation is named, never a branded drug name used as a synonym.
• Eligibility criteria and exclusions stated plainly, including who should not use the programme.
• Pricing transparency, including what happens after the introductory period. Hidden recurring billing is a misrepresentation issue as much as a conversion issue.
• Identity and contact: legal entity, address, phone or chat, and named clinical leadership.
• Policy pages reachable in one click: privacy, terms, refunds, telehealth consent.
• No before/after imagery, no unsourced average weight-loss figures, no celebrity or trial-data implication.

Lead quality is the whole game

Because you cannot buy molecule intent, the traffic you can buy is broader and needs harder qualification. Clinics that scale in this category do the qualifying before the consultation, not during it.

1. Gate on geography first. A state selector at the top of intake, matched to actual prescriber licensure, removes the largest bucket of unusable leads instantly.
2. Ask two or three clinical screening questions in the form. Conversion rate drops, qualified rate rises, and cost per qualified patient usually falls.
3. Publish price before the form. Price-hiding inflates lead volume and destroys close rate; the leads it adds were never going to buy.
4. Instrument every stage so bidding can optimise toward qualified rather than submitted — see HIPAA-conscious conversion tracking.
5. Contact within minutes. Speed to lead outweighs almost every campaign optimisation available in the interface.

The counter-intuitive result: making it harder to become a lead usually makes the account cheaper. In a restricted auction where clicks cost more, filtering early is the only way the arithmetic works.

Staying approved after you launch

Approval is a state, not an achievement, and GLP‑1 advertising is actively enforced. A maintenance routine we would consider minimum:

• Weekly search term review treated as compliance work, adding drug names and grey-market phrasing to shared negatives.
• Monthly claim audit of any page added since the last check, including landing pages built by a growth team without review.
• Quarterly policy re-read. Restricted drug terms and healthcare policy both moved in the last year; assume they will move again.
• Change log. Record what changed on the site and when, so a disapproval can be traced to a cause instead of debated.
• A rollback plan. Know which campaigns you would pause first if the account is flagged, and who has access to do it.

None of this guarantees anything — Google decides — but it is the difference between an account that recovers in days and one that argues with a reviewer for a quarter.

Why measurement decides whether this works

The compliant surface here is narrower and more expensive than the non-compliant one, so the economics only work if you can tell good leads from bad. A GLP‑1 clinic optimising to raw form fills will reliably scale itself into unqualified traffic: people outside eligibility criteria, price shoppers, and patients in states you cannot serve.

What we build before scaling spend:

• Offline conversion imports so the qualified consultation — not the form fill — is what bidding optimises toward
• Distinct conversion actions for booked, attended, qualified and started, with values that reflect real programme economics
• Consent Mode v2 and enhanced conversions configured so no patient information reaches Google, covered in HIPAA-conscious conversion tracking
• State-level geo controls matched to where your prescribers are actually licensed

Want a structured read on where your account stands? Run the Readiness Score, or book a strategy call and we will walk your current setup with you.

Frequently asked